#ACTRIMS26: Roche’s MS drug fenebrutinib beats Ocrevus, cutting risk of disability progression by 12%
#ACTRIMS26: Roche’s MS drug fenebrutinib beats Ocrevus, cutting risk of disability progression by 12%
Body unavailable. Use the original source.
#ACTRIMS26: Roche’s MS drug fenebrutinib beats Ocrevus, cutting risk of disability progression by 12%
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.